Tag

UK Archives - JAG Shaw Baker

Client News: MediaGamma Closes £2 M Round

By | News, Startups

Congrats to our client MediaGamma who closed a £2m round from the UCL Technology Fund in partnership with ParkWalk Advisors and the London Co-Investment Fund (LCIF). MediaGamma is a predictive analytics software company that uses an enterprise-grade reinforcement machine learning platform to deliver decisions in under five milliseconds. Predictive analytics MediaGamma uses its ad tech machine learning platform in programmatic advertising, building and training more accurate user-profiling and bidding algorithms that vastly reduce customer acquisition costs for their clients. Howard Watt, partner, JAG Shaw Baker believes ad tech is not going away anytime soon. “Ad tech is transformative. Nearly 90%…

Read More

Our New Cambridge Office

By | News

We are very pleased to announce our new office in Cambridge. The office is part of our ongoing commitment to the Life Sciences ecosystem in the area and throughout the UK. The Life Sciences industry is worth around £64 Billion to the UK economy. The UK government is centering part of its new life sciences strategy to make Britain a world leader in Life Sciences on Cambridge. The Cambridge Cluster is already recognised as the hub of the UK life sciences industry with more than 400 companies employing an excess of 13,000 people. Earlier this year, Sir John Bell, Life…

Read More

In Client News: Crane Venture Partners Leads $30 M Series C For AI Startup

By | Investors, News

Congratulations to our client, Crane Venture Partners on leading the Series C $30 Million funding round for London-based Onfido. Onfido uses artificial intelligence algorithms to help websites verify people’s identities by merely using a photo-based identity document and a selfie to curb hackers and security breaches that have exposed personal information of millions of people globally. This is the second round of investment for Onfido following their round of $30 Million including two of our clients Idinvest and Wellington. In an interview with TechCrunch, Scott Sage, co-founder and partner, Crane Venture Partners, said that Onfido is one of the leading data enterprise…

Read More

Bossa Raises $10 Million Series A For Its Simulation Game

By | News, Startups

Summer turns to fall, and our clients continue to show no signs of stopping. In gaming news, we advised London-based Bossa Studios on its $10 Million Series A fundraise ahead of the launch of its upcoming simulation game Worlds Adrift. Atomico led the investment with participation from existing investor, London Venture Partners. Atomico co-founder and partner Mattias Ljungman and executive-in-residence Alexis Bonte, will both join Bossa’s board of directors. In an ongoing validation of the strength of UK and European tech, Bossa will be making use of Improbable’s ground-breaking SpatialOS platform in the creation of Worlds Adrift. The Cambridge-born tech firm has…

Read More

Habito Raises £18.5 Million In A Series B Round Led By Atomico

By | News, Startups

JAG Shaw Baker is proud to have advised our client Habito, on their £18.5 Million Series B round led by Atomico. The raise supports Habito, one of the standout ‘PropTech’ companies in the UK, and their vision to leverage the large inefficiencies inherent in the mortgage market. The round brings the total raised by the company to a total of £27m and the funding will be used for marketing and other product development as well as the company’s plans to expand its offering to other parts of the mortgage process such as home and life insurance. Daniel Hegarty, CEO, Habito started the company in 2015. The JAG Shaw Baker team…

Read More

Elasmogen Inks Research Agreement To Develop New Class Of Therapeutics

By | Life Sciences, News

Congratulations to our client Elasmogen! Elasmogen, a spin-out from Aberdeen University, alongside Canada based Feldan Therapeutics, have announced a research agreement with Amgen to develop and deliver novel intracellular biologics. The collaboration combines the unique capabilities of Feldan’s Shuttle platform and Elasmogen’s soloMER™ technology to develop the delivery system and binding domains for two undisclosed intracellular targets for Amgen. Elasmogen develops new medicines based on antibody-like molecules isolated from sharks, called VNARs (variable new-antigen receptors). VNARs are found in sharks as part of their immune system and have a similar protective role to antibodies present in the human body. The…

Read More

Fake News And Its Impact On Tech Companies

By | Insights, Intellectual Property

Recently, there have been rising concerns that the public is being deceived by the unprecedented dissemination of fake news on the internet and on social media, in particular. The term fake news is a fluid concept but is generally understood to refer to fictitious reports designed to deliberately deceive readers in order to maximise internet traffic and profit. The term gained particular traction during the 2016 US presidential election following claims of harm to democratic process. Some people are taking the fight against fake news on themselves. The Fake News Challenge is a global grassroots effort of more than 100…

Read More

MyBuilder Acquired by HomeAdivsor

By | News, Startups

We ended March on a high note with some great M&A news for our client MyBuilder. The UK company was recently acquired by HomeAdvisor, an IAC company (NASDAQ: IAC) considered one of the largest home marketplaces in the world. JAG Shaw Baker represented the interests of MyBuilder and its investors, including the founder. This deal is a great example of JAG Shaw Baker’s expertise in creating the right balance between the interests of the selling parties to generate a sensible sell-side proposition to then deliver the sale to the buyer. The firm is proud to have been a part of this deal which was effectively done in a sharp two week period. According…

Read More

Parkinson’s UK Partners With Sheffield University To Create New Spin Out

By | Life Sciences, News

Our client, Parkinson’s UK, has just inked a deal with Sheffield University to create a new £1million virtual biotech company, Keapstone Therapeutics. Even though charities and academia have entered into research partnerships before, the partnership between Parkinson’s UK and Sheffield is the first time a charity has approached researchers to launch a spin-out company with the agenda to advance a particular research programme. The Life Sciences team at JAG Shaw Baker has extensive experience with spin-out companies. The team was instrumental in structuring Keapstone Therapeutics in a way that aligned with Parkinson UK’s over-arching charitable objectives, the academic principles of Sheffield University and the requirements of a high-growth company. The…

Read More

Through The Looking Glass At Unbound 2016

By | Events

JAG Shaw Baker was invited to attend Unbound London in last month. The two-day innovation event in December took a stratospheric leap into a hyper-connected future where change will occur in the blink of an eye and be driven more by society. The event kicked off in royal style with the Duke of York, Prince Andrew introducing Pitch@Palace – an initiative created by his charitable trust to guide, help and connect entrepreneurs with influencers, angels, mentors and business partners. Insightful talks and panel discussions followed, touching on topics such as augmented reality, chatbots and even digital love and relationships. Each talk…

Read More

A cookie is a small file of letters and numbers that we store on your browser or computer, phone or tablet hard drive if you agree. more information

INFORMATION ABOUT OUR USE OF COOKIES Our website uses cookies to distinguish you from other users of our website. This helps us to provide you with a good experience and also allows us to improve our website. By continuing to browse the website, you are agreeing to our use of cookies. A cookie is a small file of letters and numbers that we store on your browser or computer, phone or tablet hard drive if you agree. We use the following cookies: • Strictly necessary cookies. These are cookies that are required for the operation of our website. They include, for example, cookies that enable you to return to a previous page. • Analytical/performance cookies. They allow us to recognise and count the number of visitors and to see how visitors move around our website when they are using it. This helps us to improve the way our website works, for example, by ensuring that users are finding what they are looking for easily. The analytical/performance cookies are provided on our behalf by Google Inc. to aid with reporting of user behaviour, market research and improving website functionality. This user behaviour is analysed in order to improve this website. To see how this applies to Google Analytics, visit http://www.google.co.uk/intl/en/analytics/privacyoverview.html. You can stop tracking by Google Analytics by visiting https://tools.google.com/dlpage/gaoptout?hl=en-GB. COOKIE DURATION The strictly necessary session cookies are a temporary cookie which remains in the cookie file of your browser until you close the browser. The other cookies will remain in the cookie file of your browser after the closing of the browser, and will become active again when you reopen this website. The different cookies have different expiration dates. Following expiry of a cookie, a new version of that cookie will be downloaded when you next visit this website, unless you have withdrawn your consent in the meantime. You can block cookies by activating the setting on your browser that allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or parts of our website. Contact If you have any queries regarding this cookie policy please contact us at info@jagshawbaker.com.

Close